Last reviewed · How we verify
Efsubaglutide Alfa Injection
At a glance
| Generic name | Efsubaglutide Alfa Injection |
|---|---|
| Also known as | Drug injection |
| Sponsor | Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT) (PHASE2, PHASE3)
- Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery (PHASE4)
- The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity（SPARKLE） (PHASE2)
- A Study of 3mg Once Every Two Weeks Administration of Efsubaglutide Alfa Injection in Type 2 Diabetes Patients. (PHASE2)
- A Study of the Efficacy and Safety of Efsubaglutide Alfa in Overweight or Obesity Patients (PHASE2)
- Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: